Kissei Pharmaceutical said on July 19 that it has withdrawn its new drug application in Japan for its spinocerebellar degeneration drug rovatirelin in order to reexamine its development strategies. The drug, previously known as KPS-0373, had been filed in December…
To read the full story
Related Article
- Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
March 17, 2025
- Kissei Files Rovatirelin for Spinocerebellar Degeneration in Japan
December 24, 2021
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





